News FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. November 28, 2023 Read More » FDA Warns of Rare but Serious Drug Reaction to the Antiseizure Medicines Levetiracetam and Clobazam November 28, 2023 Read More » OGSIVEO™ November 27, 2023 Read More » Botanical-Be Issues Voluntary Nationwide Recall of Kuka Flex Forte, Artri King, and Reumo Flex (Capsules) Due to Presence of Undeclared Diclofenac November 22, 2023 Read More » RYZNEUTA® November 22, 2023 Read More » COMBOGESIC® IV November 18, 2023 Read More » TRUQAP November 17, 2023 Read More » AUGTYRO™ November 15, 2023 Read More » DEFENCATH® November 15, 2023 Read More » Page1 … Page3 Page4 Page5 Page6 Page7 … Page45 Benefit Advisors & Employees - Want to know more? Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager Full Name(Required) Email(Required) Comment(Required) Company Name(Required) CAPTCHA
FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. November 28, 2023 Read More »
FDA Warns of Rare but Serious Drug Reaction to the Antiseizure Medicines Levetiracetam and Clobazam November 28, 2023 Read More »
Botanical-Be Issues Voluntary Nationwide Recall of Kuka Flex Forte, Artri King, and Reumo Flex (Capsules) Due to Presence of Undeclared Diclofenac November 22, 2023 Read More »